Case 17: oesophageal, pancreatic, prostate, testicle Flashcards

1
Q

2 WW for oesophageal cancer (upper GI endoscopy)

A
  • Dysphagia OR
  • ≥55 with weight loss and upper abdo pain, reflux, dyspepsia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Oesophageal cancer investigations

A
  • FBC (microcytic anaemia)
  • Upper GI endoscopy and biopsy
  • Endoscopic US (EUS): tumour depth, invasion in surrounding structures and regional lymph node involvement (staging)
  • Barium swallow: less sensitive then endoscopy
  • CT: to view local invasion and distant metastases (staging)
  • PET: distant metastases or malignancies
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Oesophageal cancer surgery

A
  • In early-stage and localized disease: esophagectomy with or without lymphadenectomy and neoadjuvant chemo
  • Surgical complications: anastomotic leak, with an intrathoracic anastomosis resulting in mediastinitis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Oesophageal cancer: chemotherapy and radiation therapy

A
  • Neoadjuvant chemoradiation (administered before surgery) can improve survival in locally advanced disease and may increase the likelihood of complete tumour resection.
  • Adjuvant therapy (administered after surgery): in positive surgical margins or advanced nodal disease.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Oesophageal cancer palliative treatment

A

endoscopic stenting, dilation, laser ablation, or chemotherapy can help alleviate symptoms and improve quality of life.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Tylosis and oesophageal cancer treatment time

A

Tylosis: hyperkeratosis of the feet, is associated with oesophageal cancer

Oesophageal cancer treatment time: curative is 12-18 months, palliative is 4 months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Pancreatic cancer

A
  • Most common type: Adenocarcinoma (85%) arising from the ductal epithelium at the head of the pancreas
  • Periampullary tumour: those that arise within 2cm of the ampulla of vater
  • Poor prognosis due to late presentation average is 6 months
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Pancreatic cancer risk factors

A
  • increasing age, family history
  • smoking, alcohol
  • diabetes, obesity and consumption of red meats
  • Chronic pancreatitis, H.pylori infection
  • hereditary non-polyposis colorectal carcinoma
  • multiple endocrine neoplasia
  • BRCA2 gene
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Pancreatic cancer: clinical feature

A
  • classically painless obstructivejaundice: yellow skin, pale stools, dark urine, generalised itching
  • Courvoisier’s law: painless obstructive jaundice and a palpable gallbladder (epigastric mass) is likely pancreatic cancer
  • Anorexia, weight loss, N+V
  • loss of exocrine function (e.g.steatorrhoea)
  • loss of endocrine function (e.g. diabetes mellitus)
  • epigastric pain radiating to back (relieved n leaning forwards)
  • Trousseau’s sign: recurrent migratory thrombophlebitis, occurs in different locations over time
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Pancreatic cancer: 2WW

A
  • Over 40 with jaundice
  • Over 60 with weight loss plus an additional symptom: Diarrhoea, back pain, abdominal pain, Nausea, Vomiting, Constipation, New onset Diabetes
  • Referred for adirect access CT abdomen
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Pancreatic cancer: investigations

A
  • CA19-9: used for staging and assessing treatment response
  • US: first line
  • High resolution CT: gold standard
  • CT thorax, abdomen and pelvis (CT TAP): staging CT to look for metastasis and other cancer
  • MRCP: assess assess biliary tract
  • ERCP: to put a stent in and relieve obstruction
  • Biopsy under US or CT
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Management pancreatic cancer

A
  • <20% are suitable for surgery at diagnosis
  • Whipple’s resection (pancreaticoduodenectomy) is performed for resectable lesions in the head of pancreas. Resectable means no spread to liver, nodes or vessels
  • adjuvant chemotherapy is given following surgery
  • ERCP with stenting is often used for palliation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Types of surgery for pancreatic cancer

A
  • Total pancreatectomy
  • Distal pancreatectomy
  • Pylorus-preserving pancreaticoduodenectomy(PPPD) (modified Whipple procedure)
  • Radical pancreaticoduodenectomy(Whipple procedure)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Pancreatic cancer: Palliative treatment

A
  • Stents inserted to relieve the biliary obstruction
  • Surgery to improve symptoms (e.g., bypassing the biliary obstruction)
  • Palliative chemotherapy (to improve symptoms and extend life)
  • Palliative radiotherapy (to improve symptoms and extend life)
  • End of life care with symptom control
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Pancreatic cancer: Whipple’s procedure

A
  • Removes tumour at the head of the pancreas when its not spread
  • Need good baseline health
  • Side-effects of a Whipple’s include dumping syndrome and peptic ulcer disease
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Management of pancreatic cancer if not resectable

A
  • biliary stent insertion by ERCP to reduce jaundice and pruritus
  • chemo
  • analgesia
  • pancreatic enzymes
  • domperidone/ metoclopramide for N/V
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Risk factors for prostate cancer

A
  • Increasing age
  • Family history
  • Black African or Caribbean origin
  • Tall stature
  • Anabolic steroids

Most prostate cancers are adenocarcinomas

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Where can prostate cancer spread and how do you rate severity

A
  • seminal vesicles, bladder and rectum via lymphatics
  • bone via bloodstream

What is used to rate severity of prostate cancer: IPSS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Prostate cancer: presentation

A
  • Asymptomatic- lower urinary tract symptoms
  • Haematuria, haematospermia
  • Erectile dysfunction
  • tenesmus
  • Pain: back, perianal or testicular
  • Bladder outlet obstruction: hesitancy, urinary retention
  • Symptoms of advanced disease or metastasis (e.g., weight loss, bone pain or cauda equina syndrome)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Consider a PSA and sigital rectal exam if

A
  • Any lower urinary tract symptoms, such asnocturia, urinary frequency, hesitancy, urgency or retention or
  • erectile dysfunction or
  • visible haematuria.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Prostate exam investigations

A
  • PSA
  • Urinalysis
  • FBC, U&E, LFT
  • Digital rectal exam: hard, firm, asymmetrical, craggy or irregular
  • Prostate biopsy: do if Likert 3 or above. Can be false negative if miss the cancerous zone. Types of prostate biopsies: Transrectal ultrasound guided biopsy (TRUS), Transperineal biopsy
  • Multiparametric MRI: reported on a Likert scale
  • Isotope bone scan: to look for boney metastasis
  • Transrectal ultrasound guided (TRUS) biopsy
22
Q

Prostate cancer management

A
  • Surveillanceorwatchful waitingin early prostate cancer
  • External beam radiotherapydirected at the prostate: side effect is proctitis
  • Brachytherapy: implanting radioactive seeds into the prostate
  • Hormone therapy: Androgen receptor blocker (bicalutamide) or GnRH agonists such as goserelin or 17a hydroxylase inhibitors. Bilateral orchidectomy to remove testicles
  • Surgery: radical prostatectomy with removal of seminal vesicles
  • Alternative to surgery: radical radiotherapy (external beam, possibly with brachytherapy) with adjunct androgen deprivation therapy
23
Q

PSA levels may be raised by

A
  • Benign Prostatic Hyperplasia (BPH)
  • prostatitis and urinary tract infection (NICE recommend to postpone the PSA test for at least 1 month after treatment)
  • ejaculation (ideally not in the previous 48 hours)
  • vigorous exercise (ideally not in the previous 48 hours)
  • Urinary retention
  • instrumentation of the urinary tract
24
Q

Surveilance for early prostate cancer

A
  • active surveillance with: 6 monthly PSA, 12 monthly DRE
  • repeat multiparametric MRI at 1 year

Side effects of prostate cancer treatment: erectile dysfunction, urinary incontinence

25
Testicular cancer
- Relatively rare - Two main subtypes: Seminomas (40-60%) and non-seminomatous germ cell tumours (NSGCT 30-50%) also known as Teratoma. These are both Germ cell tumours - Non germ cell tumours: Leydig cell tumour and sarcoma - Commonly affects young Caucasian men (15-35) - Very good prognosis even in metastatic disease - Prognosis: 95% survival
26
Male germ cell cancer
- Seminomas: No reliable tumour marker but beta-HCG in 20%. Any tumour that produces AFP is considered mixed even if the pathology suggests pure seminoma. 50% of germ cell tumours. Slow growth. Responds better to radiation and chemo - Non-seminomas: disease spreads earlier so more likely to present with advanced disease. AFP and hCG markers are elevated in majority. More prone to early metastasis - Mixed: Beta-hCG and AFP - Intratubular germ cell neoplasia is the precursor to germ cell tumours
27
Testicular cancer: risk factors
- Infertility - <45 - Caucasian - HIV - Cryptorchidism: undescended testis - Family history - Klinefelter's syndrome, Down syndrome - History of testicular torsion - Mumps orchitis - 80% of testicular cancer express 12p gain - Family history
28
Testicular cancer: clinical features
- A painless lump is the most common presenting symptom - Lump: Hard, irregular, not fluctuant, no transillumination. Can cause enlargement of testicle - Can have scrotal pain or back pain - Pain is present in a minority of men - Other possible features include hydrocele, gynaecomastia (Leydig cell tumour) - Weight loss, fatigue - Can present similar to epididymo-orchitis but persists after antibiotics
29
Testicular cancer: presentation of metastatic disease
- Lung cancer or PE: dyspnoea, cough - Mediastinal mass: SVC obstruction - Retroperitoneal disease: Ureteric obstruction, abdo mass, abdo or back pain - CNS symptoms - Liver capsular pain - Advanced disease: weight loss, fatigue - Where might testicular cancer spread to: lymphatics, lungs, liver, brain
30
Testicular cancer: investigations
- Scrotal US: confirms diagnosis - Staging CT chest/abdomen/pelvis: look for areas of spread and stage the cancer. Performed after orchidectomy - AFP, hCG and LDH (elevated in germ cell tumour) - CXR: bilateral hilar lymphadenopathy, cannonball mets - CT brain if multiple lung metastases and/or serum hCG >10,000 - Genetic analysis if appropriate: Trisomy 8 and Kleinefelter's syndrome - Biopsy tumour and histology
31
Testicular cancer monitoring
- Serum tumour markers (AFP, hCG, LDH): are measured pre-orchidectomy, 24hrs post orchidectomy and weekly until normal. - Suggests absence of residual disease if hCG normalises in 24hrs and AFP in 4-6 days - In non-seminomas increased tumour markers suggest worse prognosis - Beta-hCG tends to be elevated in metastatic seminoma, testicular choriocarcinoma and non-seminomas (can falsely elevate due to marijuana) - LDH raised in seminomas and non-seminomas, associated with growth rate - AFP rises in teratomas (not seminomas)
32
Testicular cancer: factors associated with poor prognosis
- Metastasis: distant nodes and non pulmonary organs - Non-seminomas: how much serum tumour markers are elevated - Tumours originating in the mediastinum and not the testis - Histology: Non-seminoma have worse outcomes - Even patients with widespread metastasis including the brain can have curable disease and should be treated with intent
33
Staging of testicular cancer
- Stage 1: no evidence of metastasis, isolated to testicle - Stage 2: infradiaphragmatic nodal involvement - Stage 3: supradiaphragmatic nodal involvement - Stage 4: extralymphatic involvement, spread to other organs
34
Testicular cancer differentials
- Benign epididymal masses are relatively common - Epididymo-orchitis or orchitis (if not resolving within 3 weeks should be referred for urological assessment) - Lymphoma/leukaemic infiltrate
35
Testicular cancer 2ww
- Non painful enlargement or change in shape or texture of the testis - US
36
Testicular cancer management
- Treatment depends on whether the tumour is a seminoma or a non-seminoma - Orchidectomy: prosthesis can be inserted - Sperm banking: to save sperm - Chemotherapy and radiotherapy - Seminoma’s tend to respond well to radiation and chemotherapy, have better prognosis - Non-seminomas can have teratomatous elements which are resistant to chemo and may need surgery for cure.
37
Testicular cancer: when do markers return to normal after surgery
- Beta hCG: within 24 hours - AFP: within 5 days - Follow up with monitoring of tumour markers and imaging
38
Treatment of testicular cancer by stage
- Stage 1: radical inguinal orchiectomy with clamping of the spermatic cord to prevent inguinal seeding. Dont need pre-op biopsy. Just monitor cancer markers. In seminoma adjuvant radiotherapy is used in the lymph nodes. In non seminoma 2 cycles of BEB chemotherapy can reduce relapse - Stage 2A and B seminoma: radiotherapy to the lymph nodes. After orchiectomy you dissect their lymph node to confirm staging. They may then receive adjuvent chemo - For stage 3 and above you delay orchiectomy as chemo is the mainstay of treatment. You perform orchiectomy post chemo once tumour markers are stabilised - Chemo: cycles of bleomycin, etopside and cisplatin (BEP)
39
Non seminomatous testicular tumours include
- Embryonal carcinomas - Yolk sac tumours - Choriocarcinomas - Teratomas - Mixed germ cell tumours
40
Side effects of testicular cancer management
- Infertility: should be offered sperm storage but many can still conceive naturally. Recommended wait at least 3 months post chemo to conceive naturally - Secondary leukaemia: non-lymphocytic, especially with platinum based chemo and radiotherapy - Restrictive lung disease: with cisplatin based chemo, rarely causes toxic pulmonary effects, if this happens stop the drug - Hypogonadism (testosterone replacement may be required) - Peripheral neuropathy - Hearing loss - Lasting kidney, liver or heart damage - Increased risk of cancer in the future - Psycho-sexual: anxiety, depression, body image issues
41
Adverse effects of tumour lysis syndrome
- Cardiac arrest/arrhythmia's: hypocalcaemia, hyperkalaemia, hyperphosphataemia - Acute renal failure: urate nephropathy, hyperuricaemia - DIC: cell death, activation of coagulation cascade, intravascular haemolysis (high LDH)
42
Prevention and management of tumour lysis syndrome
- Prevention: adequate hydration and urine output. Allopurinol or rasburicase as urate oxidase inhibitors - Management: Requires adequate hydration and strict management of electrolytes but using a low K+ diet, oral and rectal resonium, IV calcium gluconate, IV bicarbonate, insulin/glucose, furosemide, forced hydration and in some cases haemodialysis.
43
Ovarian germ cell cancers
- 3% of ovarian cancers are germ cell tumours - Affects young women and adolescent girls - Monitor with AFP and hCG, CA!”% is often normal
44
Extragonadal germ cell tumours
- mediastinal: chest pain, SOB, cough, SVC obstruction, dysphagia, hoarseness. Presents in 30’s - retroperitoneal: few symptoms until advand - pineal region (brain): raised ICP, neurological symptos, endocrine dysfunction - sacrococcygeal - Associated with Klinefelter’s (especially mediastinal)
45
How to investigate extra-gonadal germ cell tumours and treatment
- gonadal examination and ultrasound to look for a hidden primary - CT chest abdo pelvis - biopsy of tumour - Placental ALP - Treatment: chemo and radiation
46
The 4 main types of ovarian tumours
- Surface derived tumours - Germ cell tumours - Sex cord stromal tumours - Metastasis
47
Surface derived tumours (65% of ovarian tumours)
- Serous cystadenoma: most common benign ovarian tumour, often bilateral. Cyst lined by ciliated cells - Serous cystadenocarcinoma: malignant, often bilateral. Psammoma bodies seen (collection of calcium). Most common ovarian cancer - Mucinous cystadenoma: benign, cyst lined by mucus secreting epithelium - Mucinous cystadenocarcinoma: malignant. May be associated with pseudomyxoma peritonei - Brenner tumour: benign, Contain Walthard cell rests (benign cluster of epithelial cells), similar to transitional cell epithelium. Typically have 'coffee bean' nuclei. - Epithelial origin
48
Where do surface derived ovarian tumours (Epithelial) originate from
- Serous (46%): Fallopian tube epithelium – majority of tumours - Mucinous (35%): GI tract or endocervical epithelium - Endometrioid (8%): Proliferative endometrium - Clear cell (3%): Gestational endometrium – relatively rare, aggressive, CA-125 often not raised in this type - Squamous cell (<1%) - Transitional cell (Brenner): Urinary tract epithelium (rare)
49
Germ cell tumours ovarian cancer
- Most common in adolescent girls and account for 15-20% of tumours - Teratoma- the mature teratoma (dermoid cyst) is the most common and is benign. Immature teratoma is malignant. Account for 90% of germ cell tumours, contain a combination of ectodermal i.e. hair, mesodermal i.e. bone and endodermal tissue - Dysgerminoma- most common malignant germ cell tumour. Histological appearance similar to a testicular seminoma. Associated with turners syndrome. Typically secretes hCG and LDH - Yolk sac tumour: typically secretes AFP, schiller-duval bodies on histology - Choriocarcinoma- malignant. Rare tumour that is part of the spectrum of gestational trophoblastic disease. Typically, have increased hCG levels. Characterised by early haematogenous spread to the lungs
50
Sex cord stromal tumours- ovarian cancer
- Around 3-5% of ovarian tumours, often produce hormones - Granulosa cell tumour: malignant, produces oestrogen, leading to precocious puberty if in children or endometrial hyperplasia in adults. Contains Call-Exner bodies (small eosinophilic fluid filled spaces between granulosa cells) - Sertoli-Leydig cell tumour: benign, produces androgens causing a masculinizing effect. Associated with Peutz-Jegher syndrome - Fibroma- benign. Associated with Meigs syndrome (ascites, pleural effusion). Solid tumour consisting of bundles of spindle shaped fibroblasts. Typically occur around the menopause, classically causing a pulling sensation in the pelvis.